Skip to content
Clinical Trials – home

Centrum Neurologii Krzysztof Selmaj

VerifiedinfoResponsive

Poland ul. Tylna 12, 90-324 Lodz, Poland

  • 5 trials recruiting
  • Relapsing multiple sclerosis · Multiple sclerosis · Chronic inflammatory demyelinating polyradiculoneuropathy
  • Adult patients

About Specializations

Centrum Neurologii Krzysztof Selmaj in Lodz, Poland specialises in clinical trials of conditions such as Relapsing multiple sclerosis, Multiple sclerosis, Chronic inflammatory demyelinating polyradiculoneuropathy, Relapsing-remitting multiple sclerosis, and other specialisations. This site conducts important research.

Main research areas of the site

Neurology

The medical center is at the forefront of neurological research, with a particular focus on relapsing multiple sclerosis (RMS). The institution is dedicated to advancing the understanding and treatment of this complex condition through innovative research and clinical trials.

  • Relapsing Multiple Sclerosis (RMS)
  • Long-term Safety and Tolerability Studies
  • Advanced Therapeutic Interventions

By conducting extensive studies on the long-term safety and tolerability of treatments like ofatumumab, the center contributes significantly to the development of effective therapies that improve patient outcomes and quality of life.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
ul. Tylna 1290-324 LodzPoland
Recruiting now
5 trials
Conditions studied
8
Partner status
Verified

More sites in LodzPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

17 clinical trials

Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ublituximab
  • Sponsor:Tg Therapeutics Inc.
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cetirizine
  • Sponsor:Tg Therapeutics Inc.
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dnth103
  • Sponsor:Dianthus Therapeutics Inc.
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:Amgen Inc.
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Methylprednisolone
  • Sponsor:F. Hoffmann-La Roche AG
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Ublituximab
  • Sponsor:Tg Therapeutics Inc.
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Fenebrutinib
  • Sponsor:F. Hoffmann-La Roche AG
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG
Registered drug
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Fenebrutinib
  • Sponsor:F. Hoffmann-La Roche AG
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.